Skip to main content
European Commission logo print header

Synapses between Leukaemia and its Neighbouring Cells

Project description

The bone marrow niche in health and disease

Haematopoietic stem cells reside in a specific microenvironment of the bone marrow known as a niche. The niche encompasses different types of cells, the extracellular matrix, and paracrine factors that collectively support the undifferentiated state and self-renewal capacity of stem cells. The EU-funded SyLeNCe project is interested in dissecting the interaction between niche components during homeostasis and disease. Emphasis will be given to the detailed characterisation of cell relationships during malignant transformation in leukaemia as well as disease development and progression. The SyLeNCe work will offer a more holistic view of the stem cell niche and may unveil new candidates for the treatment of leukaemia.

Objective

Our understanding of the different layers of organization in tissues remains limited. Stem cell niches offer a tightly controlled environment and a unique opportunity to look into this question. Reductionist approaches have been proven highly efficient dissecting the complexity of stem cell niches in a unidirectional fashion. However, this approach fails to recognize the tri-dimensional complexity of tissue organization. Hence we propose a systems biology approach based on low input and single cell RNA sequencing of bone marrow niche populations in order to establish not only the molecular landscape of cells that comprise the stem cell niche in homeostasis and disease but also the lineage relationships that may exist between cells in the stroma. Using the mouse bone marrow niche during neoplastic transformation to acute myeloid leukemia (AML), we will first unravel the cellular and molecular interactions that constitute the tumor microenvironment during disease development and progression using multi parametric flow cytometry and RNA-sequencing. Information gathered from these experiments will also provide a list of molecular candidates for therapeutic intervention in AML. We will validate those candidate cell populations and genetic pathways by means of gain and loss-of-function assays in vitro and in vivo using murine models and primary human AML samples. Completion of our interdisciplinary project will provide, for the first time a complete transcriptional and cellular map of a tissue, revealing the heterotypic interactions that define the real nature of a tissue. Perhaps then we could start to appreciate the elegant complexity of the ecosystem that the stem cell and its niche share. I hope SyLeNCe will facilitate the description of novel vulnerabilities that could be explored therapeutically for the treatment of acute myeloid leukaemia having an impact on the quality of life and long-term survival of AML patients.

æ

Coordinator

FUNDACION PARA LA INVESTIGACION MEDICA APLICADA FIMA
Net EU contribution
€ 160 932,48
Address
Avenida de pio xii 55
31008 Pamplona
Spain

See on map

Region
Noreste Comunidad Foral de Navarra Navarra
Activity type
Research Organisations
Links
Other funding
€ 0,00